Department of Physiology, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
J Pathol. 2017 Aug;242(4):476-487. doi: 10.1002/path.4922.
Endometriosis is a highly prevalent gynaecological disease that severely reduces women's health and quality of life. Ectopic endometriotic lesions have evolved mechanisms to survive in the hypoxic peritoneal microenvironment by regulating the expression of a significant subset of genes. However, the master regulator controlling these genes remains to be characterized. Herein, by using bioinformatics analysis and experimental verification, we identified yes-associated protein 1 (YAP1) as a master regulator of endometriosis. Nuclear localization and transcriptional activity of YAP1 were up-regulated by hypoxia via down-regulation of LATS1, a kinase that inactivates YAP1. Disruption of hypoxia-induced YAP1 signalling by siRNA knockdown or inhibitor treatment abolished critical biological processes involved in endometriosis development such as steroidogenesis, angiogenesis, inflammation, migration, innervation, and cell proliferation. Treatment with a YAP1 inhibitor caused the regression of endometriotic lesions without affecting maternal fertility or the growth rate of offspring in the mouse model of endometriosis. Taken together, we identify hypoxia/LATS1/YAP1 as a novel pathway for the pathogenesis of endometriosis and demonstrate that targeting YAP1 might be an alternative approach to treat endometriosis. Copyright © 2017 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
子宫内膜异位症是一种高发的妇科疾病,严重降低了妇女的健康和生活质量。异位子宫内膜病灶已经进化出通过调节一组重要基因的表达来在缺氧的腹膜微环境中生存的机制。然而,控制这些基因的主要调节因子仍有待确定。在此,通过生物信息学分析和实验验证,我们确定 yes 相关蛋白 1(YAP1)是子宫内膜异位症的主要调节因子。缺氧通过下调使 YAP1 失活的激酶 LATS1,上调 YAP1 的核定位和转录活性。通过 siRNA 敲低或抑制剂处理破坏缺氧诱导的 YAP1 信号通路,消除了与子宫内膜异位症发展相关的关键生物学过程,如甾体生成、血管生成、炎症、迁移、神经支配和细胞增殖。YAP1 抑制剂的治疗导致子宫内膜异位病灶的消退,而不影响母鼠生育力或子宫内膜异位症小鼠模型中后代的生长速度。总之,我们确定缺氧/LATS1/YAP1 是子宫内膜异位症发病机制的一个新途径,并证明靶向 YAP1 可能是治疗子宫内膜异位症的一种替代方法。